American Diabetes Association GUIDELINES Apps - Institutional

Hyperglycemia 2012 ADA v2_eViewer

American Diabetes Association (ADA) GUIDELINES Apps brought to you free of charge courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/143157

Contents of this Issue

Navigation

Page 12 of 15

Advantages Disadvantages Cost •  No hypoglycemia •  ? ↓ CVD events (Cycloset Safety Trial) •  Generally modest HbA1c efficacy •  Dizziness/syncope •  Nausea •  Fatigue •  Rhinitis High •  No hypoglycemia •  Weight reduction •  ? Potential for improved β-cell mass/function •  ? Cardiovascular protective actions •  Gastrointestinal side effects (nausea/ vomiting) •  ? Acute pancreatitis •  C-cell hyperplasia/medullary thyroid tumors in animals •  Injectable •  Training requirements High •  ↓ Postprandial glucose excursions •  Weight reduction •  Generally modest HbA1c efficacy •  Gastrointestinal side effects (nausea/ vomiting) •  Hypoglycemia unless insulin dose is simultaneously reduced •  Injectable •  Frequent dosing schedule •  Hypoglycemia •  Weight gain •  ? Mitogenic effects •  Injectable •  Training requirements •  "Stigma" (for patients) High •  Universally effective •  Theoretically unlimited efficacy •  ↓ Microvascular risk (UKPDS) Variablee 11

Articles in this issue

Archives of this issue

view archives of American Diabetes Association GUIDELINES Apps - Institutional - Hyperglycemia 2012 ADA v2_eViewer